Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MASP2 | O00187 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethylbenzene SCHEMBL28102258 | 0.86 | SCN2A (0.49) | NPC1RAB9APOLBL3MBTL1ALDH1A1 | |
| SCHEMBL384952 | 0.83 | NPC1 (0.61) | NPC1RAB9APOLBL3MBTL1ALDH1A1 | |
| SCHEMBL24317555 | 0.80 | NPC1 (0.59) | NPC1RAB9APOLBL3MBTL1ALDH1A1 | |
| SCHEMBL13258488 | 0.80 | LMNA (0.42) | ALDH1A1MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL20812634 | 0.79 | NPC1 (0.51) | NPC1RAB9APOLBALDH1A1MEN1 | |
| SCHEMBL5219548 | 0.78 | DGAT1 (0.41) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL19569164 | 0.78 | NISCH (0.42) | RAB9APOLBL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL17948203 | 0.78 | NPC1 (0.57) | NPC1RAB9APOLBL3MBTL1ALDH1A1 | |
| SCHEMBL30808614 | 0.78 | ALDH1A1 (0.50) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL15452781 | 0.78 | ALDH1A1 (0.50) | NPC1RAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | claimed |
| EP-2074084-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2009-07-01 | — | — | EP | claimed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | claimed |
| WO-2008039645-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | WO | claimed |
| US-20250367209-A1 | IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | SOUTHERN RES INST (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-115466229-B | Para-amidobenzenesulfonyl compound and application thereof | 上海中医药大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240276957-A1 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2023250002-A1 | IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SOUTHERN RESEARCH INSTITUTE (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | NPC1 2051/4885RAB9A 3649/4885POLB 4192/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | NPC1 3/4885RAB9A 3451/4885POLB 380/4885 |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | NPC1 3651/4885RAB9A 4505/4885POLB 2514/4885 |
| US-20250367209-A1 | IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | MAPT, SORBS1, TARDBP | NPC1 3487/4885RAB9A 2694/4885POLB 3829/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | NPC1 1300/4885RAB9A 1158/4885POLB 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.